



## SUPPLEMENTARY MATERIAL 2

### Mortality


**Supplementary Figure 1.** Forest plot for mortality according to the type of vasoactive agent




**Supplementary Figure 2.** Forest plot for mortality according to Child-Pugh Classification



**Supplementary Figure 3.** Funnel plot for mortality




**Supplementary Figure 4. Egger's test for mortality**




p = 0.645

**Bleeding control**


**Supplementary Figure 5. Forest plot for bleeding control**




**Supplementary Figure 6.** Forest plot for bleeding control according to the type of vasoactive agent.




**Supplementary Figure 7.** Forest plot for bleeding control according to Child-Pugh Classification.



**Supplementary Figure 8.** Funnel Plot for bleeding control




**Supplementary Figure 9.** Egger's test for bleeding control.




$p = 0.013$

**Early rebleeding**


**Supplementary Figure 10.** Forest plot for early rebleeding.




**Supplementary Figure 11.** Forest plot for early rebleeding according to the type of vasoactive agent.



Supplementary Figure 12. Funnel plot for early rebleeding.



Supplementary Figure 13. Egger's test for early rebleeding.




p = 0.560




## Late rebleeding

Supplementary Figure 14. Forest plot for late rebleeding.




## Blood transfusion

Supplementary Figure 15. Forest plot for blood transfusion.




**Supplementary Figure 16.** Forest plot for packet blood transfusion




## Hospital stay

**Supplementary Figure 17.** Forest plot for the length of hospital stay.



## Adverse events

**Supplementary Figure 18.** Forest plot for adverse events according to the type of vasoactive agent.




**Supplementary Table 5.** Summary of the meta-analyses of adverse events according to the doses of vasoactive agents.

Subgroup	N° Studies	T-V (Events /Total)	O-S (Events /Total)	Heterogeneity test		Meta-analysis results	
				p-value	I <sup>2</sup> (%)	RR (95% CI)	p- value
Recommended dose Vasopressin vs Recommended dose Somatostatin	5	42/101	10/107	0.13	45	3.71 (1.42 to 9.70)	0.01
Recommended dose Vasopressin vs Low- dose Octreotide	2*	11/45	3/44	NA	NA	3.67 (1.17 to 11.52)	0.03
Recommended dose Terlipressin vs Recommended dose Somatostatin	2	31/133	22/134	0.10	63	0.74 (0.07 to 7.48)	0.80
Low-dose Terlipressin vs Recommended dose Somatostatin	3	42/326	12/327	0.71	0	3.31 (1.79 to 6.13)	< 0.01
Recommended dose Terlipressin vs Recommended dose Octreotide	1	18/30	8/30	NA	NA	2.25 (1.16 to 4.36)	0.02
Low-dose Terlipressin vs Low- dose Octreotide	2	62/297	31/297	0.0002	90	2.07 (0.64 to 6.75)	0.23


No.: Number, T: terlipressin, V: vasopressin, O: octreotide, S: somatostatin, RR: Risk Ratio, NA: Not applicable

\*Huang 1992 reported no adverse events in each group.

**Supplementary Figure 19.** Funnel Plot for adverse events.



Supplementary Figure 20. Egger's test for adverse events.



p = 0.160

### Sensitivity Analysis

Supplementary Figure 21. Mortality: Sensitivity analysis for risk of bias (low risk of bias).

